Decheng Capital, a venture capital firm, led a $60m Series B round in Mirvie, a health care company, with participation from BlackRock, Foresite Capital, General Catalyst, GV, Khosla Ventures, Mayfield and Comerica Bank. “At Mirvie, we find it unacceptable that pregnancy health has not advanced meaningfully in decades. We believe the Mirvie RNA platform can shape a new future of predictive, preventive, and personalized pregnancy care for the well-being of millions of expecting parents and babies. We are thrilled to welcome several top-tier investors who recognize this staggering unmet need and have backed us to make a difference,” Maneesh Jain, Mirvie Co-Founder and CEO.